Viewing Study NCT06716658


Ignite Creation Date: 2025-12-25 @ 12:14 AM
Ignite Modification Date: 2025-12-25 @ 10:16 PM
Study NCT ID: NCT06716658
Status: RECRUITING
Last Update Posted: 2025-11-18
First Post: 2024-11-29
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:

Organization Data

Organization:
Class: OTHER
Study ID: IIT2024084
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators

Collaborators

Name Class View
None OTHER View
None OTHER View
None OTHER View
None OTHER View
None OTHER_GOV View
None OTHER View
None OTHER View